Table 2.

Sample distribution.

Number of Available and Excluded Blood Samples	Number
Total:	n = 88
Pre-Treatment (PT) (n = 63) + Pilot (n = 10)	73
Mid Treatment (MT)	72
End of Treatment (EOT)	64
Follow-up (FU)	41
Plasma HPV (pHPV) detection:	n = 88
Detectable pHPV (PT or MT + Pilot)	52
Not measurable pHPV (PT + pilot) *	23
Missing PT and undetectable pHPV in remaining samples	13
P16 status and pHPV subtypes **	n = 68
PT (43 pHPV positive, 18 pHPV negative)	61
Pilot pHPV positive	5
MT pHPV positive if missing PT sample	2
Pre-treatment characteristics and survival analysis	n = 45
PT pHPV positive	45
Elimination patterns ***	n = 67
PT + Pilot positive	65
MT	60
EOT	59

* One patient with undetectable pHPV in PT, MT, and FU samples had detectable pHPV in EOT. ** 20 patients were excluded (13 had missing PT and undetectable pHPV in remaining samples, 2 PT positive had missing P16 immunohistochemical staining, 5 pilot negatives were excluded due to incomplete HPV subtype measurement). *** 21 patients were excluded due to lack of repeated measurements.